XPO1 and B-cell chronic lymphocytic leukemia: The presence of the E571 mutations increased CLL aggressiveness in in vivo models, but did not affect selinexor binding to XPO1[61], suggesting that mutation of the target, by not altering the binding of SINE to XPO1, has a marginal role in SINE resistance.